Sacituzumab Tirumotecan Advances to Frontline Therapy: New Indication Application Accepted for Triple-Negative Breast Cancer
In recent years, Antibody-Drug Conjugates (ADCs) have emerged as one of the fastest-growing classes of innovative cancer therapies, combining the […]





